Nicolás Quezada1, Rodrigo Muñoz2, Carla Morelli2, Dannae Turiel2, Julián Hernández2, Fernando Pimentel2, Alex Escalona3. 1. Department of Digestive Surgery, School of Medicine Pontificia Universidad Católica de Chile, Diagonal Paraguay 362, Cuarto Piso, Santiago, Chile. nfquezada@gmail.com. 2. Department of Digestive Surgery, School of Medicine Pontificia Universidad Católica de Chile, Diagonal Paraguay 362, Cuarto Piso, Santiago, Chile. 3. Universidad de los Andes, Santiago, Chile.
Abstract
BACKGROUND: The duodenal-jejunal bypass liner (DJBL) is an endoscopic device that mimics the duodenal-jejunal exclusion component of the Roux-en-Y gastric bypass. Previous studies assessing the efficacy of the DJBL have shown 10-40% excess weight loss (%EWL) and improvements in obesity-associated comorbidities. The aim of this study was to evaluate the safety and efficacy of a new DJBL prototype over a 3-year period. METHODS: Morbidly obese subjects were enrolled in a single-arm, open-label, prospective trial. The subjects were offered the opportunity to continue with the trial annually and signed a new consent form. The primary endpoint was safety. The secondary endpoints were changes in weight and biochemical parameters from baseline. RESULTS: The DJBL was implanted endoscopically in 80 subjects (age: 35±10 years; 69% female; weight: 109±17 kg; BMI: 42±5.4 kg/m2). Seventy-two severe adverse events (AEs) were observed in 55 patients (68%), of which nine subjects required a prolonged hospital stay and three subjects required major interventions. Overall, 23 subjects (29%) underwent early device removal due to AEs. Additionally, 95% of the patients experienced mild AEs that mainly consisted of abdominal pain. The severe AEs included a liver abscess (3), upper GI bleeding (4), cholangitis (1), and acute pancreatitis (1) and mostly occurred after 12 months of follow-up. Two patients presented a short esophageal perforation during explantation. These perforations were successfully managed with endoscopic closure in one subject and medical treatment in the other subject. In the completer population at 52 weeks (71 patients), 104 weeks (40 patients), and 156 weeks (11 patients), the mean %EWL were 44 ± 16, 40 ± 22, and 39 ± 20, respectively (p < 0.001). CONCLUSION: This study shows significant and sustained weight loss after 3 years of treatment with the new DJBL. However, the high frequency and severity of AEs preclude the use of this prototype for periods longer than 1 year.
BACKGROUND: The duodenal-jejunal bypass liner (DJBL) is an endoscopic device that mimics the duodenal-jejunal exclusion component of the Roux-en-Y gastric bypass. Previous studies assessing the efficacy of the DJBL have shown 10-40% excess weight loss (%EWL) and improvements in obesity-associated comorbidities. The aim of this study was to evaluate the safety and efficacy of a new DJBL prototype over a 3-year period. METHODS: Morbidly obese subjects were enrolled in a single-arm, open-label, prospective trial. The subjects were offered the opportunity to continue with the trial annually and signed a new consent form. The primary endpoint was safety. The secondary endpoints were changes in weight and biochemical parameters from baseline. RESULTS: The DJBL was implanted endoscopically in 80 subjects (age: 35±10 years; 69% female; weight: 109±17 kg; BMI: 42±5.4 kg/m2). Seventy-two severe adverse events (AEs) were observed in 55 patients (68%), of which nine subjects required a prolonged hospital stay and three subjects required major interventions. Overall, 23 subjects (29%) underwent early device removal due to AEs. Additionally, 95% of the patients experienced mild AEs that mainly consisted of abdominal pain. The severe AEs included a liver abscess (3), upper GI bleeding (4), cholangitis (1), and acute pancreatitis (1) and mostly occurred after 12 months of follow-up. Two patients presented a short esophageal perforation during explantation. These perforations were successfully managed with endoscopic closure in one subject and medical treatment in the other subject. In the completer population at 52 weeks (71 patients), 104 weeks (40 patients), and 156 weeks (11 patients), the mean %EWL were 44 ± 16, 40 ± 22, and 39 ± 20, respectively (p < 0.001). CONCLUSION: This study shows significant and sustained weight loss after 3 years of treatment with the new DJBL. However, the high frequency and severity of AEs preclude the use of this prototype for periods longer than 1 year.
Authors: Lars Sjöström; Anna-Karin Lindroos; Markku Peltonen; Jarl Torgerson; Claude Bouchard; Björn Carlsson; Sven Dahlgren; Bo Larsson; Kristina Narbro; Carl David Sjöström; Marianne Sullivan; Hans Wedel Journal: N Engl J Med Date: 2004-12-23 Impact factor: 91.245
Authors: Alex Escalona; Fernando Pimentel; Allan Sharp; Pablo Becerra; Milenko Slako; Dannae Turiel; Rodrigo Muñoz; Claudia Bambs; Sergio Guzmán; Luis Ibáñez; Keith Gersin Journal: Ann Surg Date: 2012-06 Impact factor: 12.969
Authors: Kristen Blythe Pitzul; Timothy Jackson; Sean Crawford; Josephine Chi Hin Kwong; Sanjeev Sockalingam; Raed Hawa; David Urbach; Allan Okrainec Journal: Obes Surg Date: 2014-01 Impact factor: 4.129
Authors: Jessica L Unick; Daniel Beavers; Dale S Bond; Jeanne M Clark; John M Jakicic; Abbas E Kitabchi; William C Knowler; Thomas A Wadden; Lynne E Wagenknecht; Rena R Wing Journal: Am J Med Date: 2013-03 Impact factor: 4.965
Authors: Keith S Gersin; Richard I Rothstein; Raul J Rosenthal; Dimitrios Stefanidis; Stephen E Deal; Timothy S Kuwada; William Laycock; Gina Adrales; Melina Vassiliou; Samuel Szomstein; Stephen Heller; Anne Marie Joyce; Frederick Heiss; Dmitry Nepomnayshy Journal: Gastrointest Endosc Date: 2010-03-20 Impact factor: 9.427
Authors: Ruben Schouten; Carianne S Rijs; Nicole D Bouvy; Wim Hameeteman; Ger H Koek; Ignace M C Janssen; Jan-Willem M Greve Journal: Ann Surg Date: 2010-02 Impact factor: 12.969
Authors: Thomas Karlas; David Petroff; Jürgen Feisthammel; Sebastian Beer; Matthias Blüher; Tatjana Schütz; Ralf Lichtinghagen; Albrecht Hoffmeister; Johannes Wiegand Journal: Obes Surg Date: 2022-06-17 Impact factor: 3.479
Authors: B Betzel; M I Cooiman; E O Aarts; I M C Janssen; P J Wahab; M J M Groenen; J P H Drenth; F J Berends Journal: Surg Endosc Date: 2019-03-14 Impact factor: 4.584
Authors: Andrea Telese; Vinay Sehgal; Cormac G Magee; S Naik; S A Alqahtani; L B Lovat; Rehan J Haidry Journal: Clin Transl Gastroenterol Date: 2021-06-18 Impact factor: 4.488